title: Hepatitis B Vaccination Coverage and Prevalence of Hepatitis B Surface Antigen Among Children in French Polynesia, 2014.
abstract: French Polynesia is considered to be moderately endemic for chronic hepatitis B virus infection, with an estimated 3% of the population having hepatitis B surface antigen (HBsAg). From 1990 to 1992, a 3-dose hepatitis B vaccination series was introduced into the routine infant immunization schedule in French Polynesia, including a birth dose (BD). In 2014, a nationally representative 2-stage cluster survey was undertaken to evaluate the impact of the vaccination program on HBsAg prevalence among school children (∼6 years of age) in Cours Préparatoire (CP). Documented vaccination data were reviewed for all eligible children; children with consent were tested for HBsAg with a rapid point-of-care test. In total, 1,660 students were identified; 1,567 (94%) had vaccination data for review and 1,196 (72%) participated in the serosurvey. Three-dose vaccination coverage was 98%, while timely BD coverage, defined as a dose administered within 24 hours of life, was 89%. Receipt of the second and third doses was often delayed, with 75% and 55% receiving a second and third dose within 1 month of the recommended age, respectively. No children tested positive for HBsAg. French Polynesia's vaccination program has achieved high coverage and an HBsAg seroprevalence of 0% (0-0.5%) among CP school children, but timeliness of vaccination could be improved.
authors.affiliation: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia hgo9@cdc.gov.
authors.forename: Minal K
authors.initials: MK
authors.lastname: Patel
authors.affiliation: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia.
authors.forename: Evelyne
authors.initials: E
authors.lastname: Le Calvez
authors.affiliation: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Wannemuehler
authors.affiliation: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Ségalin
mesh_terms: D002648:Child; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D011114:Polynesia / Q000453:epidemiology; D015995:Prevalence; D014611:Vaccination
chemical_list: D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines